Glycoprotein nonmetastatic B as a pharmacological target in cancer: structural mechanisms, druggability, and therapeutic translation.
GPNMB emerges as validated target for antibody-drug conjugates, with FDA-approved therapy and active trials expanding its clinical application.
This review in Biochemical Pharmacology synthesizes the evidence for glycoprotein nonmetastatic B (GPNMB) as a pharmacological target in melanoma, breast cancer, NSCLC, and other cancers, including its structural biology, druggability, and antibody-drug conjugate (ADC) development. The review is timely given active clinical trials for GPNMB-targeted ADCs and the recent FDA approval of glembatumumab vedotin for TNBC.
What the study was
- Study design
- Review
- Population
- Cancer patients and preclinical models for GPNMB-targeted therapy
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Biochemical pharmacology
Why it surfaced
GPNMB-targeted ADC development is clinically active. Biochemical Pharmacology review provides consolidated target validation and drug translation landscape relevant to precision oncology watchlist.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.